Trials / Completed
CompletedNCT00193544
Arsenic Trioxide and Thalidomide in the Treatment of Refractory Multiple Myeloma
Phase II Trial of Arsenic Trioxide and Thalidomide in the Treatment of Patients With Refractory Multiple Myeloma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (planned)
- Sponsor
- SCRI Development Innovations, LLC · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
In this trial, we plan to evaluate further the role of arsenic trioxide in the treatment of patients with refractory multiple myeloma. Arsenic trioxide will be used in combination with thalidomide. Although both drugs have a similar mechanism of action, it is likely that the mechanisms may be additive or synergistic. Since neither drug produces much myelosuppression, this combination regimen should be tolerable in patients with compromised marrow function due to involvement with myeloma and/or previous cytotoxic chemotherapy
Detailed description
Upon determination of eligibility, patients will be receive: * Arsenic Trioxide + Thalidomide
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Arsenic Trioxide | |
| DRUG | Thalidomide |
Timeline
- Start date
- 2002-03-01
- Primary completion
- 2005-10-01
- Completion
- 2009-01-01
- First posted
- 2005-09-19
- Last updated
- 2009-01-23
Source: ClinicalTrials.gov record NCT00193544. Inclusion in this directory is not an endorsement.